Rapid (Deuterio)difluoromethylation of Heteroatoms Using R‐22 Gas: A Demonstration of Flow Chemistry in Suppressing Intrinsic Reaction Pathways-Reference-Cited by-同舟云学术

Rapid (Deuterio)difluoromethylation of Heteroatoms Using R‐22 Gas: A Demonstration of Flow Chemistry in Suppressing Intrinsic Reaction Pathways

Published:2024-09-12 Issue: Volume: Page:
ISSN:1615-4150
Container-title:Advanced Synthesis & Catalysis
language:en
Short-container-title:Adv Synth Catal

Author:

Leung Hon Cheung¹,Lee Tsz Chun²,Wong Wing‐Tak¹,Fu Wai Chung²^ORCID

Affiliation:

1. Department of Applied Biology and Chemical Technology The Hong Kong Polytechnic University Hung Hom, Kowloon, Hong Kong People's Republic of China

2. Department of Chemistry City University of Hong Kong Tat Chee Avenue Kowloon, Hong Kong People's Republic of China

Abstract

AbstractR‐22 gas (ClCF2H) is utilized in continuous flow for the installation of CF2H and CF2D groups on heteroatoms. A judiciously designed flow system suppresses the intrinsic SN2 reaction between heteroatom anions and ClCF2H, allowing for selective carbene‐based fragment coupling to yield X‐CF2D products with deuterium incorporation levels up to 96%. A broad scope of X–CF2H and X–CF2D products (X=S, O, N) is obtained with a short residence time of 5 minutes and scalability is demonstrated.

Funder

Croucher Foundation

Hong Kong Polytechnic University

City University of Hong Kong

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/adsc.202400826

Reference88 articles.

2. Aurora Kinase Inhibitors Based on the Imidazo[1,2-a]pyrazine Core: Fluorine and Deuterium Incorporation Improve Oral Absorption and Exposure

3. Applications of Fluorine in Medicinal Chemistry

4. Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas